… However, anti-angiogenic therapy has turned out to be more complex than … this therapeutic
option calls for a reevaluation of VEGF as the major target in anti-angiogenic cancer therapy. …

… anti-angiogenic therapy 118 . Indeed, in a Phase III study, sunitinib monotherapy significantly
increased PFS in patients with PNET compared with best supportive care, … cancer patients, …

… may be of high value in breast cancer treatment. However, correlative studies have reported
… the method to identify patients who will respond to anti-angiogenic therapy, which may be …

… as an effective anti-angiogenic therapeutic, independent of other anti-angiogenic drugs. …
Therefore, this work developed a novel MIP-based anti-angiogenic drug for cancer treatment…

… to become a promising strategy in anti-tumor therapy. The most widely used anti-angiogenic …
kinase inhibitors (TKIs) targeting vascular endothelial growth factor (VEGF) pathway. …

… for cancer treatment based on the use of molecules inhibiting tumor angiogenesis and in
particular vascular-endothelial … for the treatment of human epidermal growth factor receptor 2 (…

… anti-angiogenic drugs against various types of tumors, there are two main conclusions
emerging from the results: First, anti-angiogenic … endothelial growth factor (VEGF). As VEGF acts …

… vascular endothelial growth factor (VEGF) A, was approved for the first time as an anti-angiogenic
drug for the treatment … survival in most cancer patients, some patients have little or no …

… vascular endothelial growth factor (VEGF) signaling has been identified as a central axis in
tumor … , a humanized antibody that targets VEGF and is a leading clinical therapy to suppress …

… tumor angiogenesis. As such, it remains the most studied pro-angiogenic pathway and target
of anti-angiogenic therapeutic … the vascular endothelial growth factor A/vascular endothelial …